Literature DB >> 11081161

Invasive pituitary adenomas: significance of proliferation parameters.

A P Amar1, D R Hinton, M D Krieger, M H Weiss.   

Abstract

Although most pituitary adenomas behave in a purely benign fashion, microscopic invasion of the subjacent dura is very common, and clinically overt infiltration of the surrounding dura and bone is apparent at intraoperative inspection in about one third of cases. The factors governing invasive behavior remain unknown but are believed to be separate from those regulating cell proliferation. Histological features alone do not distinguish between benign, invasive, and malignant tumors of adenohypophyseal origin. Multiple attempts have been made to identify prognostic markers of aggressive behavior among these tumors. They include cytogenetic analysis of putative tumor suppressor genes or proto-oncogenes as well as immunohistochemical detection of cell-cycle specific antigens. At present, however, these analyses can neither distinguish the indolent pituitary adenoma from one that will pursue an invasive course, nor reliably predict the prognosis in individual patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11081161     DOI: 10.1023/a:1009931413106

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  40 in total

1.  p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.

Authors:  K Thapar; B W Scheithauer; K Kovacs; P J Pernicone; E R Laws
Journal:  Neurosurgery       Date:  1996-04       Impact factor: 4.654

Review 2.  The cytogenesis and pathogenesis of pituitary adenomas.

Authors:  S L Asa; S Ezzat
Journal:  Endocr Rev       Date:  1998-12       Impact factor: 19.871

3.  Matrix metalloproteinase-9 secretion by human pituitary adenomas detected by cell immunoblot analysis.

Authors:  H Kawamoto; K Kawamoto; T Mizoue; T Uozumi; K Arita; K Kurisu
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

4.  Dural invasion and proliferative potential of pituitary adenomas.

Authors:  G Daita; Y Yonemasu
Journal:  Neurol Med Chir (Tokyo)       Date:  1996-04       Impact factor: 1.742

5.  Overexpression of the growth-hormone-releasing hormone gene in acromegaly-associated pituitary tumors. An event associated with neoplastic progression and aggressive behavior.

Authors:  K Thapar; K Kovacs; L Stefaneanu; B Scheithauer; D W Killinger; R V Lioyd; H S Smyth; A Barr; M O Thorner; B Gaylinn; E R Laws
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

6.  Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: marker of tumour invasiveness.

Authors:  I Shimon; D R Hinton; M H Weiss; S Melmed
Journal:  Clin Endocrinol (Oxf)       Date:  1998-01       Impact factor: 3.478

7.  Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67.

Authors:  E Knosp; K Kitz; A Perneczky
Journal:  Neurosurgery       Date:  1989-12       Impact factor: 4.654

8.  Invasiveness of pituitary adenomas.

Authors:  D Sautner; W Saeger
Journal:  Pathol Res Pract       Date:  1991-06       Impact factor: 3.250

Review 9.  Malignant prolactinomas.

Authors:  E A Popovic; J R Vattuone; K H Siu; I Busmanis; M J Pullar; J Dowling
Journal:  Neurosurgery       Date:  1991-07       Impact factor: 4.654

10.  Heterogenous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas.

Authors:  S Ezzat; H S Smyth; L Ramyar; S L Asa
Journal:  J Clin Endocrinol Metab       Date:  1995-03       Impact factor: 5.958

View more
  16 in total

Review 1.  Clinical review: Pituitary carcinoma: difficult diagnosis and treatment.

Authors:  Anthony P Heaney
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

2.  DNA-flow cytometry of 207 pituitary adenomas: ploidy, proliferation, and prognosis.

Authors:  A L O Machado; P Nomikos; F Kiesewetter; R Fahlbusch; M Buchfelder
Journal:  J Endocrinol Invest       Date:  2005-10       Impact factor: 4.256

3.  Cyclins D1 and D3 and topoisomerase II alpha in inactive pituitary adenomas.

Authors:  W Saeger; S Schreiber; D K Lüdecke
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

Review 4.  Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).

Authors:  Nèle Lenders; Ann McCormack
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 5.  My approach to pathology of the pituitary gland.

Authors:  N Y Y Al-Brahim; S L Asa
Journal:  J Clin Pathol       Date:  2006-12       Impact factor: 3.411

Review 6.  Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?

Authors:  Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

7.  MicroRNA involvement in a metastatic non-functioning pituitary carcinoma.

Authors:  Zhenqing Wei; Cuiqi Zhou; Mei Liu; Yong Yao; Jian Sun; Jianqi Xiao; Wenbin Ma; Huijuan Zhu; Renzhi Wang
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

Review 8.  Management of aggressive pituitary adenomas and pituitary carcinomas.

Authors:  Anthony Heaney
Journal:  J Neurooncol       Date:  2014-03-02       Impact factor: 4.130

9.  Intraoperative optical identification of pituitary adenomas.

Authors:  M Sam Eljamel; Graham Leese; Harry Moseley
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

Review 10.  In search of a prognostic classification of endocrine pituitary tumors.

Authors:  Jacqueline Trouillas
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.